Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3… Dec 3, 2021
Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection… Nov 16, 2021
PharmaDrug Announces pre-IND Meeting Request Granted by FDA for Oral Antiviral Drug Cepharanthine for the Treatment of… Sep 28, 2021
Revive Therapeutics: Remains Discounted To Peers As Oral COVID Therapeutics Race Heats Up Aug 11, 2021